LOS ANGELES--(BUSINESS WIRE)--Pharmaco-Kinesis Corporation (PKC), an advanced medical device company developing smart implantable pumps and medications for local drug delivery, today reported development of the first combinatorial nano-drug product candidate, a combination of Temozolomide (Merck & Co.) and Thalidomide (Celgene) nanoparticles to be tested for treatment of gliomas and other cancers.
Based on the collaboration with University of California, San Diego’s Department of NanoEngineering at the Moores Cancer Center, PKC is planning development and testing of the nano-droplet TNT™, a combination of Temozolomide, an anti-cancer drug from Merck & Co., Inc., and Thalidomide, an anti-cancer drug from Celgene Corporation, in a formulation with ratio of 50% Temozolomide and 50% Thalidomide.
If this potentially groundbreaking achievement by PKC proves effective, pharmaceutical companies may seek to use this technique in a manner, which allows them simultaneously to dissolve at body temperature in their nano-format. PKC believes 2,000 to 20,000 molecules of each type of drug can be packaged in one nano-droplet and preliminary tests indicate that the ratio of these different drugs can be precisely controlled. PKC intends that these nano-droplets will be produced with special affinities for cancer cells, attaching to and destroying such cells with enhanced efficacy compared to traditional drug treatment. PKC has commenced in vivo lab tests of TNT™, and preliminary results indicate that the nano-drug combination has substantially more efficacy than formulations of these drugs currently in use by physicians.
PKC predicts that direct local site delivery will be required to achieve the potentially high efficacy of the nano-drugs. PKC is in the process of developing a microminiaturized Metronomic Biofeedback Pump Nano (MBPn) version, a fully implantable infusion pump that enables programmable, metronomic, local delivery and sampling via a multi-channel catheter that has the potential to avoid elimination by the liver. PKC hopes that the MBPn will increase therapeutic efficacy of drugs while reducing their side effects in comparison with current systemic delivery methods.
“We are conducting ongoing development and testing in order to prove the efficacy of delivering proprietary nano-droplet formulations of anti-cancer medications using our MBP,” said Frank Adell, CEO of PKC. “If these tests are successful, we believe PKC will produce a major advance in treating gliomas and potentially other types of cancer as well.”